David S. Simmons net worth and biography

David Simmons Biography and Net Worth

Director of Viatris

Mr. Simmons currently serves as Chief Executive Officer of Caliber Holdings Corporation and Senior Advisor to Abingworth LLP. Prior to joining Caliber Holdings, Mr. Simmons served as Operating Partner with Hellman & Friedman LLC, held management roles of increasing responsibility at PPD, Inc., including Executive Chairman and Chief Executive Officer, and at Pfizer Inc., where he most recently held the position of President and General Manager, Emerging Markets and Established Products. Mr. Simmons’ previous board service includes tenures at Curia Global, Inc. (Albany Molecular Research Inc. prior to 2021), Launch Therapeutics, Inc., Medline Industries, Inc. and Owens & Minor, Inc.

Mr. Simmons' qualifications to serve on the Board include, among others, his experience and expertise regarding public company management, finance, accounting and capital markets, global business, information security, and strategy and M&A. Mr. Simmons also brings healthcare industry and human capital management experience to the Board.

What is David S. Simmons' net worth?: The estimated net worth of David S. Simmons is at least $15.98 thousand as of November 3rd, 2025. Mr. Simmons owns 1,183 shares of Viatris stock worth more than $15,982 as of March 13th. This net worth approximation does not reflect any other investments that Mr. Simmons may own. Learn More about David S. Simmons' net worth.
How do I contact David S. Simmons?: The corporate mailing address for Mr. Simmons and other Viatris executives is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. Viatris can also be reached via phone at (724) 514-1800 and via email at [email protected]. Learn More on David S. Simmons' contact information.
Has David S. Simmons been buying or selling shares of Viatris?: David S. Simmons has not been actively trading shares of Viatris during the past quarter. Most recently, on Monday, November 3rd, David S. Simmons bought 213 shares of Viatris stock. The stock was acquired at an average cost of $10.43 per share, with a total value of $2,221.59. Following the completion of the transaction, the director now directly owns 1,183 shares of the company's stock, valued at $12,338.69. Learn More on David S. Simmons' trading history.
Who are Viatris' active insiders?: Viatris' insider roster includes Paul Campbell (CAO and Corporate Controller), W. Cornwell (Director), Robert Coury (Chairman), Michael Goettler (CEO), James Kilts (Director), Corinne Le Goff (Chief Commercial Officer), JoElleng Lyons Dillon (Director), Rajiv Malik (Director), Brian Roman (Chief Legal Officer), David Simmons (Director), Scott Smith (CEO), Menassie Taddese (insider), and Pauline van der Meer Morh (Director). Learn More on Viatris' active insiders.
Are insiders buying or selling shares of Viatris?: During the last twelve months, Viatris insiders bought shares 4 times. They purchased a total of 82,499 shares worth more than $761,381.71. During the last twelve months, insiders at the sold shares 1 times. They sold a total of 7,032 shares worth more than $72,078.00. The most recent insider tranaction occured on November, 3rd when Director David S Simmons bought 213 shares worth more than $2,221.59. Insiders at Viatris own 0.3% of the company. Learn More about insider trades at Viatris.
Information on this page was last updated on 11/3/2025.

David S. Simmons Insider Trading History at Viatris

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/3/2025	Buy	213	$10.43	$2,221.59	1,183
8/27/2025	Buy	286	$10.42	$2,980.12	970

David S. Simmons Buying and Selling Activity at Viatris

Viatris Company Overview

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Today's Range

Now: $13.51

$13.48

$13.97

50 Day Range

MA: $14.18

$12.37

$16.13

2 Week Range

Now: $13.51

$6.85

$16.47

Volume

8,965,604 shs

Average Volume

11,240,595 shs

Market Capitalization

$15.56 billion

P/E Ratio

N/A

Dividend Yield

3.48%

Beta

0.78